Ken Griffin Bio Xcel Therapeutics, Inc. Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$0.53 - $1.34 $901 - $2,278	1,700 Added 8.29%	22,200 $13,000
Q2 2024 Aug 14, 2024	BUY	$1.14 - $2.97 $9,804 - $25,542	8,600 Added 72.27%	20,500 $26,000
Q1 2024 May 15, 2024	SELL	$1.95 - $4.04 $88,920 - $184,224	-45,600 Reduced 79.3%	11,900 $33,000
Q4 2023 Feb 14, 2024	BUY	$2.32 - $5.51 $55,911 - $132,791	24,100 Added 72.16%	57,500 $169,000
Q3 2023 Nov 14, 2023	SELL	$2.49 - $11.85 $162,846 - $774,990	-65,400 Reduced 66.19%	33,400 $84,000
Q2 2023 Aug 14, 2023	BUY	$6.39 - $28.58 $367,425 - $1.64 Million	57,500 Added 139.23%	98,800 $658,000
Q1 2023 May 15, 2023	SELL	$17.7 - $33.24 $927,480 - $1.74 Million	-52,400 Reduced 55.92%	41,300 $770,000
Q4 2022 Feb 14, 2023	SELL	$10.25 - $22.43 $142,475 - $311,777	-13,900 Reduced 12.92%	93,700 $2.01 Million
Q3 2022 Nov 14, 2022	BUY	$11.19 - $17.89 $89,520 - $143,120	8,000 Added 8.03%	107,600 $1.27 Million

3.2M

22.2K

40.2K

Ticker BTAI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,022,500
Market Cap $16M
Description
BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and prop...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.